Lexaria Bioscience Corp. (NASDAQ: LEXX) to Address Advances in its Bioavailability Technology DehydraTECH(TM) at Wainwright Life Sciences Conference

• Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments
• Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes
• The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process
• The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream

As life sciences technology innovator Lexaria Bioscience (NASDAQ: LEXX) takes a leap forward in R&D programs demonstrating the effectiveness of its trademarked oral substance delivery platform, the company is preparing to join other participants in the 23rd annual Global Investor Conference hosted by full-service investment bank H.C. Wainwright & Co. The investor conference scheduled Sept. 13-15 will be a hybrid online and in-person gathering of companies enjoying opportunities for platform presentations, one-on-one meetings with investors, and… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office [email protected] CBDWire is part of the InvestorBrandNetwork.